Redesigning the Rules: How FEP+ Helped Us Design a Differentiated SOS1 Inhibitor
Mutations in the KRAS protein are among the most common drivers of many cancers, including pancreatic, colorectal, and non-small cell lung cancers. KRAS acts as a molecular switch, and when it’s stuck in the “on” position, it drives uncontrolled cell growth.